Semaglutide, a glucagon-like peptide-1 receptor agonist, has gained recognition for its role in managing weight, blood sugar, and even alcohol cravings. Both its injectable and oral forms have been widely studied, and a recent clinical trial highlights its potential to lower cardiovascular risks in people with type 2 diabetes and related conditions.

A study led by researchers at the UNC School of Medicine, including endocrinologist John Buse and cardiologist Matthew Cavender, examined the impact of oral semaglutide on cardiovascular health. Their findings suggest that this medication significantly reduces the likelihood of major cardiovascular events in individuals dealing with type 2 diabetes, atherosclerotic cardiovascular disease, or chronic kidney disease. The results were published in the New England Journal of Medicine and presented at a major scientific conference.

Type 2 diabetes is a progressive condition that makes blood sugar management increasingly difficult. As the disease advances, individuals often develop complications such as high blood pressure and high cholesterol, both of which elevate the risk of heart disease. Since heart attacks and strokes are among the most severe complications of diabetes, treatments that mitigate these risks are crucial.


Semaglutide, a glucagon-like peptide-1 receptor agonist, has gained recognition for its role in managing weight, blood sugar, and even alcohol cravings. Both its injectable and oral forms have been widely studied, and a recent clinical trial highlights its potential to lower cardiovascular risks in people with type 2 diabetes and related conditions.

A study led by researchers at the UNC School of Medicine, including endocrinologist John Buse and cardiologist Matthew Cavender, examined the impact of oral semaglutide on cardiovascular health. Their findings suggest that this medication significantly reduces the likelihood of major cardiovascular events in individuals dealing with type 2 diabetes, atherosclerotic cardiovascular disease, or chronic kidney disease. The results were published in the New England Journal of Medicine and presented at a major scientific conference.

Type 2 diabetes is a progressive condition that makes blood sugar management increasingly difficult. As the disease advances, individuals often develop complications such as high blood pressure and high cholesterol, both of which elevate the risk of heart disease. Since heart attacks and strokes are among the most severe complications of diabetes, treatments that mitigate these risks are crucial.

For more details please visit our website - https://www.medhealthinsight.com/oral-semaglutide-greatly-lowers-heart-attack-stroke-risk-in-type-2-diabetes/